{"id":"W2560704457","doi":"10.1016/s1470-2045(16)30624-6","title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":961,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Oxford","keywords":"Nivolumab; Ipilimumab; Medicine; Tolerability; Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Adverse effect; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003734068,0.001981157,0.002731945,0.0004913421,0.0005290761,0.001676163,0.001058406,0.001672437,0.002763827],"category_scores_gemma":[0.002551839,0.0009486742,0.002949941,0.0005631314,0.001110814,0.001782045,0.0004508407,0.002918649,0.0008367244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219717,"about_ca_system_score_gemma":0.001175039,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001634911,"about_ca_topic_score_gemma":0.003121032,"domain_scores_codex":[0.9987181,0.0007443323,0.00005133091,0.000244088,0.0001049757,0.0001371151],"domain_scores_gemma":[0.9984348,0.0005133307,0.0003188884,0.0002228401,0.000103837,0.0004062736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9481148,0.01428009,0.00541743,0.0005415175,0.003687005,0.00006380218,0.00009134047,0.0009180941,0.003694024,0.00006050598,0.001008125,0.02212324],"study_design_scores_gemma":[0.7826654,0.186597,0.02123707,0.00005828284,0.005404721,0.000148791,0.0001095884,0.001369185,0.001143418,0.0001666496,0.001032748,0.0000672618],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947753,0.002128334,0.0003072507,0.0002028134,0.0001569618,0.0006818435,0.0009991815,0.00006421207,0.0006840279],"genre_scores_gemma":[0.993687,0.001407067,0.0008652543,0.0005887907,0.0002065228,0.0005838005,0.001584747,0.00003320241,0.001043635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003734068,"threshold_uncertainty_score":0.01974785,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08906368332496893,"score_gpt":0.4350249849294019,"score_spread":0.345961301604433,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}